pds0101,pembrolizumab
pds biotech,merck
['pds0101', 'headandneck', 'keytruda', 'pdsbio', 'pds bio']
dr. erminia massarelli, oncologist from city of hope, takes part in the panel review of the interim data from versatile-002 (pds0101/keytruda) for advanced #headandneckcancer at #asco23. dr. katharine price from mayo clinic was lead author of the abstract. #oncology #cancer 
PDS Biotech is a clinical-stage biotech company developing cancer therapies and infectious disease vaccines based on Versamune®, a T-cell activating technology.